Table 3.
Results of meta-regression analysis for overall survival.
| Variable | Β | P |
|---|---|---|
| Median age | 0.452 | 0.548 |
| Duration of follow-up | −0.056 | 0.944 |
| Proportion pre-menopausal | −0.903 | 0.097 |
| Proportion with visceral disease | 0.723 | 0.277 |
| Proportion with bone only | −0.651 | 0.349 |
| Proportion LRT in control group | 0.268 | 0.827 |
| Proportion of HR positive | −0.475 | 0.525 |
| Proportion of HER2 positive | −0.411 | 0.589 |
| Proportion of triple negative | −0.883 | 0.311 |
Abbreviations: HER2 – human epidermal growth factor receptor 2, HR – hormone receptor, LRT-locoregional therapy.